OKYO Pharma to Present at the Stifel 2026 Healthcare Conference

OKYO Pharma (Nasdaq: OKYO) will participate in the Stifel 2026 Healthcare Conference, scheduled for November 10–12, 2026, in New York.

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) will participate in the Stifel 2026 Healthcare Conference, scheduled for November 10–12, 2026, in New York.

CEO Robert J. Dempsey is scheduled to present at 9:20 a.m. ET on November 12 at the Lotte New York Palace Hotel. Leadership will also be available for one-on-one investor meetings throughout the conference. A live webcast will be available, with a replay archived for 90 days in the Events & Presentation area of the company’s investor website.

Argus 15 min delay 2 alerts

-5.20% vs previous close $1.36 last price 1.2x rel. volume Open Argus

Details

Market Reaction – OKYO

$1.35 – $1.44 Day Range

$71.14M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for OKYO is 5.20% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $1.36.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

neuropathic corneal pain

1 terms

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026.

Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026, at the Stifel 2026 Healthcare Conference to be held at the Lotte New York Palace Hotel, New York, NY. In addition to presenting, OKYO Leadership will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Stifel representative.

A live webcast of the presentation at the Stifel 2026 Healthcare Conference will be available at Stifel Live Webcast. Following the conference, the webcast will be archived for 90 days and available on the OKYO Events & Presentation section of the Investor section of the OKYO Pharma website.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

Investor inquiries or meeting requests:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: ir@okyopharma.com